Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting

Int J Tuberc Lung Dis. 2021 Mar 1;25(3):228-230. doi: 10.5588/ijtld.20.0586.

Authors

L Cates¹, V Crudu², A Codreanu³, N Ciobanu², H Fosburgh⁴, T Cohen⁴, N A Menzies¹

Affiliations

¹ Harvard T H Chan School of Public Health, Boston, MA, USA.
² Chiril Draganiuc Institute of Phthisiopneumology, Chisinau, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova.
³ Chiril Draganiuc Institute of Phthisiopneumology, Chisinau.
⁴ Yale University School of Public Health, New Haven, CT, USA.

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Antitubercular Agents / therapeutic use
Costs and Cost Analysis
Humans
Laboratories
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant* / diagnosis
Tuberculosis, Multidrug-Resistant* / drug therapy
Tuberculosis, Multidrug-Resistant* / epidemiology

Substances

Antitubercular Agents